Cerevel Goes Public In SPAC Merger To Fund Neuroscience Programs

 
• By Mandy Jackson

Deal Snapshot: The $445m Cerevel gains will help as it plans to have at least six programs in the clinic within the next year. CEO Tony Coles will head up a public firm for the first time since Amgen bought Onyx. 

Business teamwork puzzle pieces.
Cerevel will have $445m for neuroscience programs after it combines with Arya II • Source: Shutterstock

More from Deals

More from Business